Establishment	O
of	O
active	O
chromatin	O
structure	O
at	O
enhancer	O
elements	O
by	O
mixed	B-GENE
-	I-GENE
lineage	I-GENE
leukemia	I-GENE
1	E-GENE
to	O
initiate	O
estrogen	O
-	O
dependent	O
gene	O
expression	O
.	O


A	O
number	O
of	O
genome	O
-	O
wide	O
analyses	O
have	O
revealed	O
that	O
estrogen	B-GENE
receptor	I-GENE
alpha	E-GENE
binding	O
to	O
and	O
regulation	O
of	O
its	O
target	O
genes	O
correlate	O
with	O
binding	O
of	O
FOXA1	S-GENE
,	O
a	O
pioneer	O
factor	O
,	O
to	O
nearby	O
DNA	O
sites	O
in	O
MCF	O
-	O
7	O
breast	O
cancer	O
cells	O
.	O


The	O
enhancer	O
element	O
-	O
specific	O
histone	O
H3K4me1	O
/	O
2	O
mark	O
is	O
enriched	O
at	O
the	O
specific	O
FOXA1	S-GENE
/	O
ERalpha	S-GENE
recruitment	O
sites	O
in	O
chromatin	O
,	O
but	O
the	O
mechanism	O
by	O
which	O
these	O
enhancer	O
marks	O
are	O
established	O
in	O
chromatin	O
before	O
hormone	O
treatment	O
is	O
unclear	O
.	O


Here	O
,	O
we	O
show	O
that	O
mixed	B-GENE
-	I-GENE
lineage	I-GENE
leukemia	I-GENE
1	E-GENE
(	O
MLL1	S-GENE
)	O
protein	O
is	O
a	O
key	O
determinant	O
that	O
maintains	O
permissive	O
chromatin	O
structure	O
of	O
the	O
TFF1	S-GENE
enhancer	O
region	O
.	O
MLL1	S-GENE
occupies	O
the	O
TFF1	S-GENE
enhancer	O
region	O
and	O
methylates	O
H3K4	O
before	O
hormone	O
stimulation	O
.	O


In	O
vitro	O
,	O
MLL1	S-GENE
binds	O
directly	O
to	O
the	O
CpG	O
-	O
rich	O
region	O
of	O
the	O
TFF1	S-GENE
enhancer	O
,	O
and	O
its	O
binding	O
is	O
dependent	O
on	O
hypomethylation	O
of	O
DNA	O
.	O


Furthermore	O
,	O
the	O
depletion	O
of	O
MLL1	S-GENE
in	O
MCF	O
-	O
7	O
cells	O
results	O
in	O
a	O
dramatic	O
decrease	O
of	O
chromatin	O
accessibility	O
and	O
recruitment	O
of	O
FOXA1	S-GENE
and	O
ERalpha	S-GENE
to	O
the	O
enhancer	O
element	O
.	O


Our	O
study	O
defines	O
the	O
mechanism	O
by	O
which	O
MLL1	S-GENE
nucleates	O
histone	O
H3K4	O
methylation	O
marks	O
in	O
CpG	O
-	O
enriched	O
regions	O
to	O
maintain	O
permissive	O
chromatin	O
architecture	O
and	O
allow	O
FOXA1	S-GENE
and	O
estrogen	B-GENE
receptor	I-GENE
alpha	E-GENE
binding	O
to	O
transcriptional	O
regulatory	O
sites	O
in	O
breast	O
cancer	O
cells	O
.	O
